CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues:
Total revenues	$ 7,803	$ 7,082	$ 14,763	$ 13,749
Costs and expenses:
Cost of goods sold	1,579	1,501	3,023	3,041
Research and development expenses	1,764	1,491	3,136	2,870
Acquired in-process research and development expenses	11,183	61	11,290	315
In-process research and development impairments	1,750	190	1,750	190
Selling, general and administrative expenses	1,921	1,365	3,372	2,623
Total costs and expenses	18,197	4,608	22,571	9,038
Operating (loss) income	(10,394)	2,474	(7,808)	4,711
Interest expense	247	254	487	513
Other (income) expense, net	(387)	(208)	(621)	120
(Loss) income before income taxes	(10,254)	2,429	(7,674)	4,077
Income tax expense	242	468	801	802
Net (loss) income	$ (10,496)	$ 1,960	$ (8,475)	$ 3,275
Basic (loss) earnings per share (in dollars per share)	$ (8.45)	$ 1.57	$ (6.82)	$ 2.63
Diluted (loss) earnings per share (in dollars per share)	$ (8.45)	$ 1.56	$ (6.82)	$ 2.61
Shares used in basic (loss) earnings per share calculation (in shares)	1,243	1,245	1,243	1,246
Shares used in diluted (loss) earnings per share calculation (in shares)	1,243	1,255	1,243	1,257
Product sales
Revenues:
Total revenues	$ 7,627	$ 7,054	$ 14,574	$ 13,668
Royalty, contract and other revenues
Revenues:
Total revenues	$ 176	$ 27	$ 189	$ 81

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating Activities:
Net (loss) income	$ (8,475)	$ 3,275
Adjustments to reconcile Net (loss) income to Net cash provided by operating activities:
Depreciation expense	191	190
Amortization expense	1,196	1,197
Stock-based compensation expense	449	434
Deferred income taxes	(408)	(377)
Net (gain) loss from equity securities	(485)	284
Acquired in-process research and development expenses	12,150	315
In-process research and development impairments	1,750	190
Other, net	423	124
Changes in operating assets and liabilities:
Accounts receivable, net	(199)	(213)
Inventories	(197)	(398)
Prepaid expenses and other	(8)	93
Accounts payable	(49)	(267)
Income tax assets and liabilities, net	142	(1,852)
Accrued and other liabilities	(364)	(410)
Net cash provided by operating activities	6,117	2,584
Investing Activities:
Purchases of marketable debt securities	(551)	(2,287)
Proceeds from sales of marketable debt securities	3,544	295
Proceeds from maturities of marketable debt securities	37	15
Acquisitions, including in-process research and development, net of cash acquired	(11,318)	(294)
Purchases of equity securities	(35)	(37)
Purchases of property, plant and equipment	(257)	(211)
Other investing activities, net	3	(13)
Net cash used in investing activities	(8,577)	(2,531)
Financing Activities:
Proceeds from debt financing, net of issuance costs	4,085	0
Proceeds from issuances of common stock	175	279
Repurchases of common stock under repurchase programs	(774)	(1,257)
Repayments of debt and other obligations	(2,783)	(1,771)
Payments of dividends	(2,069)	(2,004)
Other financing activities, net	(529)	(240)
Net cash used in financing activities	(1,895)	(4,993)
Effect of exchange rate changes on cash and cash equivalents	(30)	92
Net change in cash and cash equivalents	(4,385)	(4,848)
Cash and cash equivalents at beginning of period	7,564	9,991
Cash and cash equivalents at end of period	$ 3,179	$ 5,144

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 3,179	$ 7,564
Short-term marketable debt securities	0	68
Accounts receivable, net	5,055	4,913
Inventories	1,953	1,774
Prepaid and other current assets	3,759	4,024
Total current assets	13,945	18,342
Property, plant and equipment, net	5,833	5,606
Long-term marketable debt securities	0	2,974
Intangible assets, net	14,032	16,978
Goodwill	8,314	8,314
Deferred tax assets	2,487	1,964
Other long-term assets	4,751	4,845
Total assets	49,362	59,023
Current liabilities:
Accounts payable	674	715
Accrued rebates	4,233	4,337
Current portion of long-term debt, net	2,414	2,807
Other current liabilities	3,699	3,953
Total current liabilities	11,020	11,813
Long-term debt, net	23,832	22,129
Long-term income taxes payable	943	896
Deferred tax liabilities	333	402
Other long-term liabilities	1,490	1,165
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding	0	0
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,241 shares issued and outstanding	1	1
Additional paid-in capital	9,532	8,932
Accumulated other comprehensive income	95	39
Retained earnings	2,200	13,730
Total Gilead stockholders’ equity	11,829	22,703
Noncontrolling interest	(84)	(84)
Total stockholders’ equity	11,744	22,618
Total liabilities and stockholders’ equity	$ 49,362	$ 59,023